Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 6037-6042

  Goodwin, Pamela J ^a   Ennis, Marguerite ^a   Fantus, I George ^a   Pritchard, Kathleen I ^a   Trudeau, Maureen E ^a   Koo, Jarley ^a   Hood, Nicky ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; INSULIN; LEPTIN; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTIDIABETIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ANGIOGENESIS; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSAL SYNDROME; METASTASIS; MONOTHERAPY; MULTIVARIATE ANALYSIS; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; BLOOD; BREAST TUMOR; COHORT ANALYSIS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LEPTIN; MIDDLE AGED; NEOPLASM STAGING; OBESITY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 24944469632     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.048     Document Type: Article

References (16)

1. Chlebowski RT, Aiello E, McTiernan A: Weight loss in breast cancer patient management. J Clin Oncol 20:1128-1143, 2002
2. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002
3. Papa V, Belfiore A: Insulin receptors in breast cancer: Biological and clinical role. J Endocrinol Invest 19:324-333, 1996
4. Frasca F, Pandini G, Scalia P, et al: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288, 1999
5. Boyd DB: Insulin and cancer. Integr Cancer Ther 2:315-329, 2003
6. Sandhu MS, Dunger DB, Giovannucci EL: Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94:972-980, 2002
7. Rose DP, Gilnooly EM, Nixon DW: Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (review). Int J Oncol 21:1285-1292, 2002
8. Huang L, Li C: Leptin: A multifunctional hormone. Cell Res 10:81-92, 2000
9. Fung TT, Rimm EB, Spiegelman D, et al: Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. Am J Clin Nutr 73:61-67, 2001
10. Harvie M, Hooper L, Howell AH: Central obesity and breast cancer risk: A systematic review. Obes Rev 4:157-173, 2003
11. Stephenson GD, Rose DP: Breast cancer and obesity: An update. Nutr Cancer 45:1-16, 2003
12. Petridou E, Papadiamantis Y, Markopoulos C, et al: Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 11:383-388, 2000
13. Ozet A, Arpaci F, Ilker Yilmaz M, et al: Effects of tamoxifen on serum leptin level in patients with breast cancer. Jpn J Clin Oncol 31:424-427, 2001
14. Mantzoros CS, Bolhke K, Moschos S, et al: Leptin in relation to carcinoma in situ of the breast: A study of pre-menopausal cases and controls. Int J Cancer 80:523-526, 1999
15. Stattin P, Soderberg S, Biessy C, et al: Plasma leptin and breast cancer risk: A prospective study in northern Sweden. Breast Cancer Res Treat 86:191-196, 2004
16. Doelle GC: The clinical picture of metabolic syndrome. An update on this complex of conditions and risk factors. Postgrad Med 116: 30-32, 35-38, 2004